Insulin Pens.Insulin pens, which contain cartridges of insulin, have been available for some time. Until recently, they were fairly complicated and difficult to use. Newer prefilled pens (Humulin Pen, Humalog) are disposable and allow the patient to dial in the correct amount.
Inhaled Aerosol. In 2006, the FDA approved the first non-injected form of insulin. Exubera is an inhaled form of insulin. It is approved for adults but should not be used by patients who smoke or have quit smoking within the past 6 months. Patients with asthma, bronchitis, or emphysema should also not use inhaled insulin. Scientists are also developing other types of non-injected insulin, including spray formulas.
Other Alternative Insulin Delivery Methods. Another promising avenue of investigation for delivering insulin is the use of ultrasound pulses.
Supplementary Drugs
Pramlintide (Symlin) is a new type of injectable drug that can help control postprandial hyperglycemia, the sudden increase in blood sugar after a meal. Pramlintide is injected before meals and can help lower blood sugar levels in the 3 hours after meals. Pramlintide is used in addition to insulin for patients who take insulin regularly but still need better blood sugar control. The FDA approved this drug in 2005 for adults with type 1 and type 2 diabetes. Pramlintide and insulin are the only two drugs approved for treatment of type 1 diabetes.
Pramlintide is a synthetic form of amylin, a hormone that is related to insulin. Side effects may include nausea, vomiting, abdominal pain, headache, fatigue, and dizziness. Patients with type 1 diabetes have an increased risk of severe low blood sugar (hypoglycemia) that may occur within 3 hours following a pramlintide injection. This drug should not be used if patients have trouble knowing when their blood sugar is low or have slow stomach emptying (gastroparesis).
Investigational Drugs
CD3-Antibodies. A new type of drug called a CD3 antibody is showing promise for helping patients newly diagnosed with type 1 diabetes. In phase II clinical trials, patients received the drug for 6 days. Results from a 2005 trial published in the New England Journal of Medicine indicated that the CD3 antibody helped stimulate the patients’ natural insulin production and decreased their need for insulin drug therapy. The beneficial effects lasted up to 18 months after CD3 treatment. Researchers think that this drug affects the autoimmune response involved in type 1 diabetes and helps preserve the residual beta cell function of the pancreas.
Previous Section
